Dr. Petrylak on Atezolizumab in Bladder Cancer

Daniel P. Petrylak, MD
Published: Tuesday, Dec 15, 2015



Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

In the phase I trial, it was demonstrated that patients that had high levels of PD-L1 staining in the immune cells, either 2+ or 3+, had a better survival than those patients who had 0-1+ PD-L1 levels, says Petrylak.

However, even those patients who had had 0-1+ PD-L1 levels, still benefited, with a median survival of eight months. The 2+/3+ patient group has not yet reached median survival, he adds.

This is an active drug in bladder cancer, says Petrylak.


Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

In the phase I trial, it was demonstrated that patients that had high levels of PD-L1 staining in the immune cells, either 2+ or 3+, had a better survival than those patients who had 0-1+ PD-L1 levels, says Petrylak.

However, even those patients who had had 0-1+ PD-L1 levels, still benefited, with a median survival of eight months. The 2+/3+ patient group has not yet reached median survival, he adds.

This is an active drug in bladder cancer, says Petrylak.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x